Q1 Earnings Forecast for NMRA Issued By HC Wainwright

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for Neumora Therapeutics in a research report issued on Monday, December 16th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.46) per share for the quarter. HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics' Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS and Q4 2025 earnings at ($0.44) EPS.

A number of other equities analysts have also recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $23.40.

Neumora Therapeutics Price Performance

Shares of NMRA traded down $0.68 during trading hours on Wednesday, hitting $10.18. The stock had a trading volume of 951,750 shares, compared to its average volume of 745,483. The firm has a market capitalization of $1.64 billion, a P/E ratio of -5.44 and a beta of 3.34. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00. The firm has a 50 day simple moving average of $11.88 and a 200-day simple moving average of $11.54.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period last year, the company earned ($1.14) EPS.

Institutional Trading of Neumora Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Amalgamated Bank increased its position in Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company's stock worth $29,000 after buying an additional 2,402 shares during the last quarter. Quarry LP purchased a new stake in Neumora Therapeutics in the 2nd quarter worth about $98,000. SkyOak Wealth LLC purchased a new stake in Neumora Therapeutics during the second quarter valued at about $147,000. Principal Financial Group Inc. purchased a new stake in Neumora Therapeutics during the second quarter valued at about $166,000. Finally, Intech Investment Management LLC bought a new position in Neumora Therapeutics during the third quarter worth about $175,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

Insider Buying and Selling

In related news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the sale, the director now directly owns 20,100 shares in the company, valued at approximately $342,303. This trade represents a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Robert A. Lenz sold 5,563 shares of the company's stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the completion of the transaction, the insider now owns 322,966 shares of the company's stock, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is owned by corporate insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.